Our Pricing

Understanding the Fatty Liver Test Name and Diagnostic Process in the UK

When your GP suspects fatty liver disease, understanding the fatty liver test name and what each diagnostic measure reveals is essential for managing your liver health effectively. At Cured Pharmacy, our clinical team regularly supports patients through liver health monitoring, helping you understand test results and nutritional support options available across the UK.

What Is the Fatty Liver Test Name Used by UK GPs?

There isn't a single fatty liver test name — diagnosis typically involves a combination of blood tests, imaging studies, and clinical assessment. The most common initial screening is the liver function test (LFT), which measures enzymes and proteins that indicate liver health [1]. Your GP will specifically look at alanine aminotransferase (ALT) and aspartate aminotransferase (AST), two enzymes that become elevated when liver cells are damaged.

The ALT test is particularly sensitive for detecting non-alcoholic fatty liver disease (NAFLD), with levels above 40 IU/L in men and 30 IU/L in women often prompting further investigation [1]. However, it's important to note that up to 30% of people with confirmed fatty liver disease have normal ALT levels, which is why GPs use multiple diagnostic approaches rather than relying on a single fatty liver test name [2].

Beyond standard LFTs, UK clinicians increasingly use the Enhanced Liver Fibrosis (ELF) test, a specialised blood panel that assesses three markers of liver scarring: hyaluronic acid, procollagen III N-terminal peptide, and tissue inhibitor of metalloproteinase 1 [3]. An ELF score above 10.51 suggests advanced fibrosis and typically warrants referral to hepatology services.

Liver Function Test Names and What They Measure

A comprehensive liver function test includes several specific markers, each revealing different aspects of liver health. Alanine aminotransferase (ALT) is the most liver-specific enzyme, predominantly found in liver cells and released into the bloodstream when those cells are damaged [1]. Aspartate aminotransferase (AST) is less specific, as it's also present in heart and muscle tissue, but the AST/ALT ratio helps clinicians distinguish between different types of liver disease.

Alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT) indicate bile duct function and can be elevated in fatty liver disease, particularly when there's concurrent cholestasis [2]. Albumin and total protein measurements assess the liver's synthetic function — its ability to produce essential proteins. Bilirubin levels, which measure the breakdown product of red blood cells, indicate how effectively your liver processes waste products.

The prothrombin time (PT) or international normalised ratio (INR) evaluates blood clotting factors produced by the liver, becoming prolonged only in advanced liver disease. NICE guidelines recommend that any persistently abnormal LFT results should prompt investigation for underlying causes, including NAFLD, which affects approximately 25% of the UK population [3].

Understanding Your LFT Results

Your GP will interpret LFT results in context with your medical history, body mass index, and metabolic health markers. Mild ALT elevations (1.5 to 2 times the upper limit of normal) are common in early NAFLD and may respond well to lifestyle modifications including weight reduction and nutritional support. Persistent elevations or progressive increases warrant imaging studies to assess liver fat content and exclude other liver pathologies [2].

Imaging Tests for Fatty Liver Disease Diagnosis

While blood tests provide biochemical evidence of liver dysfunction, imaging studies directly visualise liver fat accumulation. Ultrasound scanning is the most commonly used initial imaging modality in UK primary care, offering a non-invasive, radiation-free assessment of liver echogenicity [4]. A 'bright liver' appearance on ultrasound suggests steatosis, though this finding becomes apparent only when at least 20-30% of liver cells contain fat.

FibroScan (transient elastography) has become the gold standard for assessing both liver fat content and fibrosis stage in UK hepatology clinics. This specialised ultrasound technique measures liver stiffness in kilopascals (kPa), with readings below 7 kPa considered normal and values above 12 kPa suggesting significant fibrosis [4]. The controlled attenuation parameter (CAP) score simultaneously quantifies fat content, with values above 280 dB/m indicating moderate to severe steatosis.

Magnetic resonance imaging (MRI) with proton density fat fraction (MRI-PDFF) provides the most accurate non-invasive measurement of liver fat percentage but is typically reserved for research settings or cases where diagnosis remains uncertain. CT scanning can detect fatty liver but involves radiation exposure and is less sensitive than MRI for quantifying fat content [3].

Supporting Liver Health with Nutritional Supplementation

While no supplement can reverse established fatty liver disease, targeted nutritional support may complement lifestyle modifications in managing NAFLD. Vitamin E has shown promise in clinical trials, with daily doses of 800 IU improving liver histology in non-diabetic adults with non-alcoholic steatohepatitis (NASH), though long-term safety data remain limited [5].

Comprehensive multivitamin formulations like Forceval Multivitamins & Minerals Capsules (from £46.59) provide broad-spectrum micronutrient support that may benefit patients with NAFLD, who often have concurrent deficiencies in vitamins A, D, and E due to impaired fat absorption. Vitamin D deficiency is particularly prevalent in NAFLD patients and correlates with disease severity, though supplementation trials have shown mixed results regarding liver outcomes [5].

Omega-3 fatty acids, particularly EPA and DHA, demonstrate anti-inflammatory properties that may reduce liver fat content, with meta-analyses showing modest improvements in hepatic steatosis markers when combined with caloric restriction [6]. However, omega-3 supplementation alone without dietary changes has not consistently improved liver enzymes or fibrosis markers in clinical trials.

When to Consider Nutritional Support

Our superintendent pharmacist Tarun Kumar advises that nutritional supplementation should complement, not replace, evidence-based lifestyle interventions for NAFLD management. Weight reduction of 7-10% through caloric restriction and increased physical activity remains the most effective treatment for reducing liver fat and improving fibrosis scores [5]. Supplements may be particularly beneficial for patients with documented deficiencies or those unable to meet nutritional requirements through diet alone.

Advanced Diagnostic Tests: When Blood Tests Aren't Enough

When initial screening suggests significant liver disease, UK hepatologists employ more sophisticated diagnostic approaches. The Enhanced Liver Fibrosis (ELF) test, available through NHS pathways and some private laboratories, combines three serum biomarkers to generate a score predicting fibrosis stage with approximately 80% accuracy [3]. This non-invasive alternative to liver biopsy helps stratify patients into low, intermediate, or high risk categories for progressive disease.

The FIB-4 index and NAFLD Fibrosis Score are calculated risk scores using readily available laboratory values (age, ALT, AST, platelet count, albumin) to estimate fibrosis probability. A FIB-4 score below 1.3 has a high negative predictive value for excluding advanced fibrosis, while scores above 2.67 suggest significant scarring warranting specialist referral [4]. These scores are particularly useful in primary care settings where access to FibroScan may be limited.

Liver biopsy remains the definitive diagnostic test for NAFLD, providing histological grading of steatosis, inflammation, and fibrosis stage. However, given its invasive nature and sampling variability, biopsy is typically reserved for cases where non-invasive tests yield conflicting results or when concurrent liver pathology is suspected [3]. The NAFLD Activity Score (NAS) derived from biopsy specimens quantifies disease severity on a scale from 0 to 8.

Monitoring Fatty Liver Disease: Follow-Up Testing Protocols

NICE guidelines recommend that patients with confirmed NAFLD undergo regular monitoring to detect disease progression. Initial follow-up typically includes repeat LFTs every 6-12 months, with more frequent testing for those with elevated baseline values or concurrent metabolic syndrome [3]. The trajectory of ALT levels over time provides more valuable prognostic information than single measurements.

Patients with intermediate or high-risk fibrosis scores should have annual FibroScan assessments where available, as liver stiffness measurements can detect progression from simple steatosis to fibrotic NASH. A sustained increase in liver stiffness of more than 20% warrants hepatology review and consideration of emerging pharmacological therapies currently in clinical trials [4].

Metabolic monitoring is equally important, as NAFLD is strongly associated with type 2 diabetes, dyslipidaemia, and cardiovascular disease. Annual HbA1c, lipid profiles, and cardiovascular risk assessments should accompany liver-specific testing. Weight loss of just 3-5% can significantly reduce liver fat content, while 7-10% weight reduction may reverse inflammation and early fibrosis [5].

Supporting Your Liver Health Journey

At Cured Pharmacy, we stock evidence-based nutritional supplements that may support liver health as part of a comprehensive management plan. Products like Forceval Multi Vitamin (from £46.59) provide essential micronutrients that support metabolic health, while Floradix Liquid Iron & Vitamin Formula (from £46.59) addresses iron deficiency that can occur with advanced liver disease. All recommendations should be discussed with your GP or hepatologist to ensure they complement your individualised treatment plan.

Scientific References

1. Newsome, P. N., et al. (2021). Guidelines on the management of abnormal liver blood tests. Gut, 70(1), 1-16. https://doi.org/10.1136/gutjnl-2020-321792
2. Mofrad, P., et al. (2003). Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values. Hepatology, 37(6), 1286-1292. https://doi.org/10.1053/jhep.2003.50229
3. National Institute for Health and Care Excellence. (2016). Non-alcoholic fatty liver disease (NAFLD): assessment and management [NG49]. NICE. https://www.nice.org.uk/guidance/ng49
4. Castera, L., et al. (2019). Noninvasive Assessment of Liver Disease in Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 156(5), 1264-1281. https://doi.org/10.1053/j.gastro.2018.12.036
5. Chalasani, N., et al. (2018). The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 67(1), 328-357. https://doi.org/10.1002/hep.29367
6. Parker, H. M., et al. (2012). Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. Journal of Hepatology, 56(4), 944-951. https://doi.org/10.1016/j.jhep.2011.08.018

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication or supplement regimen, particularly if you have been diagnosed with liver disease or are taking other medications.